Breast Cancer Trial, Recruiting (NCT07071272)

Breast Cancer Trial, Recruiting NCT07071272 Sponsor: Azienda Ospedaliera Universitaria Integrata Verona Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07071272 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are a woman who is about to be admitted to hospital and has already been diagnosed with invasive breast cancer (at an early to moderate stage, known as T1-2)
You are 30 years of age or older
Your mammogram shows a breast density pattern rated above level 1 on a standard scale used by doctors (called BI-RADS)
You are willing and able to sign a written consent form to take part in the research
You have no history of bad reactions to the types of dye used in certain scans (iodine-based dye or gadolinium-based dye, used in CT or MRI scans)
Your kidneys are working well enough, based on a blood test taken within the last three months showing your kidney function is above a certain level (confirm with trial site)

Who may not be able to join:

Women who have breast implants
Women who are under 30 years of age
Women who have any medical reason that means they cannot safely have an MRI scan
Women who are known to carry a change in the BRCA1 or BRCA2 genes (genetic mutations linked to a higher risk of breast cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07071272

Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

More information: https://clinicaltrials.gov/study/NCT07071272

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are a woman who is about to be admitted to hospital and has already been diagnosed with invasive breast cancer (at an early to moderate stage, known as T1-2)
You are 30 years of age or older
Your mammogram shows a breast density pattern rated above level 1 on a standard scale used by doctors (called BI-RADS)
You are willing and able to sign a written consent form to take part in the research
You have no history of bad reactions to the types of dye used in certain scans (iodine-based dye or gadolinium-based dye, used in CT or MRI scans)
Your kidneys are working well enough, based on a blood test taken within the last three months showing your kidney function is above a certain level (confirm with trial site)

Who may not be able to join:

Women who have breast implants
Women who are under 30 years of age
Women who have any medical reason that means they cannot safely have an MRI scan
Women who are known to carry a change in the BRCA1 or BRCA2 genes (genetic mutations linked to a higher risk of breast cancer)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Registry

ClinicalTrials.gov

Start date

1 September 2020

Est. completion

31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Diagnostic accuracy of the CEDM against breast MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov